John R. Goffin

5.7k total citations
72 papers, 2.3k citations indexed

About

John R. Goffin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, John R. Goffin has authored 72 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in John R. Goffin's work include Lung Cancer Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (18 papers) and Colorectal Cancer Treatments and Studies (9 papers). John R. Goffin is often cited by papers focused on Lung Cancer Diagnosis and Treatment (22 papers), Lung Cancer Treatments and Mutations (18 papers) and Colorectal Cancer Treatments and Studies (9 papers). John R. Goffin collaborates with scholars based in Canada, United States and Australia. John R. Goffin's co-authors include Elizabeth A. Eisenhauer, Peter Ellis, William D. Foulkes, Pierre O. Chappuis, William K. Evans, Louis R. Bégin, Nora Wong, Andrew Arnold, Arwa Ali and Yee Ung and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

John R. Goffin

70 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John R. Goffin Canada 24 988 833 765 560 423 72 2.3k
Kathleen C. Torkko United States 29 900 0.9× 916 1.1× 661 0.9× 424 0.8× 438 1.0× 46 2.6k
Francesco Schettini Italy 22 861 0.9× 641 0.8× 493 0.6× 463 0.8× 173 0.4× 113 2.0k
John Hilton Canada 25 1.2k 1.2× 616 0.7× 828 1.1× 364 0.7× 209 0.5× 162 2.6k
Ellis Levine United States 26 1.1k 1.1× 946 1.1× 641 0.8× 664 1.2× 274 0.6× 92 2.8k
Begoña Bermejo Spain 26 1.5k 1.5× 544 0.7× 643 0.8× 924 1.6× 205 0.5× 143 2.5k
Laura Orlando Italy 27 1.9k 1.9× 543 0.7× 946 1.2× 1.3k 2.4× 321 0.8× 92 2.9k
Filipa Lynce United States 21 1.3k 1.3× 456 0.5× 571 0.7× 474 0.8× 323 0.8× 110 1.9k
Orit Freedman Canada 18 1.5k 1.6× 1.3k 1.5× 254 0.3× 718 1.3× 344 0.8× 40 2.3k
Carla I. Falkson United States 26 1.8k 1.9× 528 0.6× 811 1.1× 797 1.4× 196 0.5× 95 2.8k
Christian Schem Germany 24 913 0.9× 402 0.5× 790 1.0× 839 1.5× 167 0.4× 124 2.2k

Countries citing papers authored by John R. Goffin

Since Specialization
Citations

This map shows the geographic impact of John R. Goffin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Goffin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Goffin more than expected).

Fields of papers citing papers by John R. Goffin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Goffin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Goffin. The network helps show where John R. Goffin may publish in the future.

Co-authorship network of co-authors of John R. Goffin

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Goffin. A scholar is included among the top collaborators of John R. Goffin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Goffin. John R. Goffin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goffin, John R., et al.. (2021). Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. PLoS ONE. 16(5). e0251886–e0251886. 9 indexed citations
2.
Pond, Gregory R., et al.. (2021). A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer. BMC Cancer. 21(1). 14–14. 6 indexed citations
3.
Goffin, John R., Gregory R. Pond, Serge Puksa, et al.. (2020). Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population. BMC Pulmonary Medicine. 20(1). 300–300. 13 indexed citations
4.
Taghizadeh, Niloofar, Alain Tremblay, Sonya Cressman, et al.. (2019). Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. BMJ Open. 9(1). e024719–e024719. 38 indexed citations
5.
Dam, Alje P. van, Marissa Slaven, K.J. Ellis, et al.. (2019). Resource Use in the Last Three Months of Life by Lung Cancer Patients in Southern Ontario. Current Oncology. 26(4). 247–252. 4 indexed citations
6.
7.
Evans, William S., W. Michael Flanagan, Cindy L. Gauvreau, et al.. (2018). MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience. Journal of Thoracic Oncology. 13(10). S419–S419. 2 indexed citations
8.
Evans, William K., Cindy L. Gauvreau, S. Memon, et al.. (2017). OA17.02 Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada. Journal of Thoracic Oncology. 12(1). S309–S309. 1 indexed citations
9.
Goffin, John R., Gregory R. Pond, Alain Tremblay, et al.. (2017). Use of a marketing plan for recruitment to a lung cancer screening study.. Journal of Clinical Oncology. 35(15_suppl). 1548–1548. 1 indexed citations
10.
Wheatley‐Price, Paul, Quincy S. Chu, Maria Bonomi, et al.. (2016). A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. Journal of Thoracic Oncology. 11(11). 2018–2021. 29 indexed citations
11.
Flanagan, W. Michael, et al.. (2015). Performance of the cancer risk management model lung cancer screening module.. PubMed. 26(5). 11–8. 17 indexed citations
12.
Brade, Anthony, Robert M. MacRae, Scott A. Laurie, et al.. (2015). Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer. Clinical Lung Cancer. 17(2). 133–141. 8 indexed citations
13.
Goffin, John R. & Kevin Zbuk. (2013). Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics. 35(9). 1282–1303. 70 indexed citations
14.
Goffin, John R. & Gregory R. Pond. (2011). Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials. BMC Medical Research Methodology. 11(1). 164–164. 2 indexed citations
15.
Mukherjee, Som D., John R. Goffin, Valerie H. Taylor, Kelly K. Anderson, & Gregory R. Pond. (2011). Early stopping rules in oncology: Considerations for clinicians. European Journal of Cancer. 47(16). 2381–2386. 6 indexed citations
16.
Renouf, Daniel J., Patricia A. Tang, Pierre Major, et al.. (2011). A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Investigational New Drugs. 30(3). 1203–1207. 21 indexed citations
17.
Chappuis, Pierre O., John R. Goffin, Nora Wong, et al.. (2005). Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Annals of Oncology. 16(5). 735–742. 39 indexed citations
18.
Goffin, John R., C. Savage, Dongsheng Tu, et al.. (2004). The difference between study recommendations, stated policy, and actual practice in a clinical trial. Annals of Oncology. 15(8). 1267–1273. 1 indexed citations
19.
Robson, Mark E., Pierre O. Chappuis, Jaya M. Satagopan, et al.. (2003). A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Research. 6(1). R8–R17. 212 indexed citations
20.
Foulkes, William D., et al.. (2002). HLA-DR4 and risk of spondyloarthropathy. Journal of Medical Genetics. 39(6). 409–409. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen C. Torkko Breakdown of academic impact, for papers by Francesco Schettini Breakdown of academic impact, for papers by John Hilton Breakdown of academic impact, for papers by Ellis Levine Breakdown of academic impact, for papers by Begoña Bermejo Breakdown of academic impact, for papers by Laura Orlando Breakdown of academic impact, for papers by Filipa Lynce Breakdown of academic impact, for papers by Orit Freedman Breakdown of academic impact, for papers by Carla I. Falkson Breakdown of academic impact, for papers by Christian Schem
Rankless by CCL
2026